Clinical Trial Update: A Study to Evaluate the Long-term Safety and Tolerability of Lucerastat in Adult Subjects With Fabry Disease [Phase 3]

View source ↗

Summary

This document provides an update on a Phase 3 long-term safety and tolerability study of Lucerastat in adult patients with Fabry disease.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fabry Disease

Drugs mentioned

• Lucerastat (lucerastat)

Snippet

Sponsor: Idorsia Pharmaceuticals Ltd. | Conditions: Fabry Disease | Phase 3 | Status: ACTIVE_NOT_RECRUITING